Fig. 2From: The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysisComparison of time to progression and overall survival. a Time to progression between combination therapy and TACE. b Overall survival between combination and TACE. c Overall survival between combination and sorafenibBack to article page